Nov 6, 2026, 3:09 PMBiotechnology
Moderna Stock Jumps on 25% 2026 Growth Outlook, Cancer Vaccine in Focus
Moderna lifted its 2026 revenue outlook, projecting growth of up to 25%, as its shares jumped and investors awaited Moderna's next cancer-vaccine update.
Listen to this briefingAudio briefing
Summary
Moderna raised its full-year 2026 revenue outlook on November 6, saying revenue could grow as much as 25%. MarketWatch reported that the biotechnology company's stock jumped after the revision.
Investor attention now turns to Moderna's cancer vaccine, but the available feed summary supplied no trial, regulatory, timing or financial details. It also omitted the previous forecast, projected revenue dollars and size of the share move, limiting further assessment.
Positives
- Moderna raised its full-year revenue outlook for 2026.
- Revenue could grow as much as 25% in 2026 under the revised outlook.
- Moderna's stock jumped after the outlook increase, according to MarketWatch's headline.
Risks & concerns
- The feed did not disclose Moderna's prior revenue outlook, preventing measurement of the revision.
- The summary provided no projected revenue dollars or actual year-to-date revenue.
- The available summary gave no cancer-vaccine milestone, timing or expected financial contribution.
- The size of Moderna's stock move was not provided.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/modernas-stock-jumps-after-biotech-raises-sales-outlook-65363127?mod=mw_rss_topstories
Read full article

